Pfizer drops ImmuCell
Biotech heavyweight Pfizer has terminated a product development agreement with ImmuCell concerning the bovine health product Mast Out, the Portland biotech firm said today.
Michael Brigham, ImmuCell's CEO, told Mainebiz this morning that Pfizer's decision was purely market driven and is not a reflection of any regulatory or technical hurdles encountered with the product, which treats mastitis in dairy cows. Under the agreement, Pfizer in 2004 took over product testing and would have shepherded the product through the federal Food and Drug Administration approval process.
Brigham said the change of plans means more work for ImmuCell, which currently has 31 employees, and may lead to more hires. Pfizer's decision "does have a big impact," Brigham said. "It changes us from a support role that was pretty minor to now we're directly driving this car to FDA approval."
ImmuCell plans to stick with Pfizer's timeline and hopes to bring the product before the FDA in 2009.
Most Recent
Most Recent
Comments